Compare Nvidia Corp (NVDA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs TransMedics Group Inc — how do they compare? Nvidia Corp trades at $230.93 (market cap $5.57T), while TransMedics Group Inc trades at $80.47 (market cap $2.74B). The key difference: Nvidia Corp is far larger — about 2032.8× TransMedics Group Inc's market cap, and Nvidia Corp pays a 0.43% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and TransMedics Group Inc for 24 Days on average.
| NVDA | TMDX | |
|---|---|---|
Market Cap | $5.57T | $2.74B |
Volume | 117,720,595 | 949,331 |
Sector | Technology | Health |
52-Week High | $239.27 | $150.42 |
52-Week Low | $165.17 | $61.99 |
Typical Hold Time | 115 Days | 24 Days |
Enterprise Value | $5.54T | $3.13B |
Dividend Yield | 0.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid a broader tech sector rotation. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 55.84% net income margin and consistent earnings beats. Revenue growth accelerated to $130.50 billion in 2025, with analyst consensus remaining overwhelmingly positive.
The outlook for NVDA is favorable, driven by sustained AI chip demand and a $339.17 average price target implying significant upside. Key risks include heightened competition, market volatility from geopolitical tensions, and the stock's premium valuation. Long-term growth prospects remain robust, though near-term volatility may persist.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
